India’s ‘other’ COVID vaccines: The status of under-trial, approved and unused jabs

As India nears the 200-crore COVID-19 vaccination mark, Serum Institute of India’s (SII) Covishield accounts for 80 per cent (154 crore) of the jabs, while Bharat Biotech’s Covaxin accounts for 16.75 per cent (32 crore) jabs. 

Of the 191 crore jabs administered till now, the remaining three vaccines used — Gamelaya’s Sputnik –V, Biological E’s Corbevax and Novovax-SII’s Covovax — account only for 3.25 per cent (6.25 crore) altogether.

As of date, India has granted emergency usage authorisation (EUA) to nine COVID-19 vaccine candidates in total – Covishield, Covaxin, Covovax, Corbevax, Zydus Cadila’s ZyCoV-D, Moderna’s Spikevax, Sputnik-V, Sputnik Light, and Johnson & Johnson’s (J&J) Ad26.COV2.S.